These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24621837)

  • 1. Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction.
    Gheorghiade M; Vaduganathan M; Shah SJ
    JACC Heart Fail; 2013 Apr; 1(2):123-6. PubMed ID: 24621837
    [No Abstract]   [Full Text] [Related]  

  • 2. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.
    Maier LS; Layug B; Karwatowska-Prokopczuk E; Belardinelli L; Lee S; Sander J; Lang C; Wachter R; Edelmann F; Hasenfuss G; Jacobshagen C
    JACC Heart Fail; 2013 Apr; 1(2):115-22. PubMed ID: 24621836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
    Maier LS
    J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
    Jacobshagen C; Belardinelli L; Hasenfuss G; Maier LS
    Clin Cardiol; 2011 Jul; 34(7):426-32. PubMed ID: 21538388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine: a new approach to treating an old problem.
    Reddy BM; Weintraub HS; Schwartzbard AZ
    Tex Heart Inst J; 2010; 37(6):641-7. PubMed ID: 21224931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on evidence for treatment with ranolazine in stable angina.
    Carbone F; Montecucco F; Mach F
    Swiss Med Wkly; 2013; 143():w13874. PubMed ID: 24163124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia?
    Cocco G
    Expert Opin Pharmacother; 2012 Dec; 13(17):2429-32. PubMed ID: 23121536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for late Na current, arrhythmias, and diastolic dysfunction.
    Maier LS
    Curr Heart Fail Rep; 2012 Sep; 9(3):183-91. PubMed ID: 22767404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Symptomatic coronary heart disease therapy: ranolazine reduces frequency of angina in diabetic patients].
    MMW Fortschr Med; 2013 Mar; 155 Spec No 1(1):20. PubMed ID: 24260912
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetes and coronary disease: a need for new therapies for an expanding disease burden.
    Lew WY; DeMaria AN
    J Am Coll Cardiol; 2013 May; 61(20):2046-7. PubMed ID: 23500323
    [No Abstract]   [Full Text] [Related]  

  • 13. Ranolazine: clinical applications and therapeutic basis.
    Hawwa N; Menon V
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):5-16. PubMed ID: 23335347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel.
    Hale SL; Leeka JA; Kloner RA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):418-23. PubMed ID: 16617168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation.
    Doshi D; Morrow JP
    Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
    Makielski JC; Valdivia CR
    Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-anginal and anti-ischemic effects of late sodium current inhibition.
    Wimmer NJ; Stone PH
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):69-77. PubMed ID: 23247666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Ranolazine in Heart Failure-Current Concepts.
    Kourampi I; Katsioupa M; Oikonomou E; Tsigkou V; Marinos G; Goliopoulou A; Katsarou O; Kalogeras K; Theofilis P; Tsatsaragkou A; Siasos G; Tousoulis D; Vavuranakis M
    Am J Cardiol; 2023 Dec; 209():92-103. PubMed ID: 37844876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review.
    D'Elia E; Fiocca L; Ferrero P; Iacovoni A; Baio P; Medolago G; Duino V; Gori M; Gavazzi A; Senni M
    J Clin Pharmacol; 2013 Jun; 53(6):665-9. PubMed ID: 23585217
    [No Abstract]   [Full Text] [Related]  

  • 20. Ranolazine: an antianginal drug with antiarrhythmic properties.
    Tamargo J; Caballero R; Delpón E
    Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.